XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma.
XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma.
复制标题
DOI：
10.3390/jpm10030128
复制
发表时间：
2020-09-15
影响因子：
--
通讯作者：
Chen CY
中科院分区：
文献类型：
--
作者：
Le NQK;Do DT;Chiu FY;Yapp EKY;Yeh HY;Chen CY
大约96%的胶质母细胞瘤（GBM）患者具有IDH 1野生型GBM，其特征在于预后极差，部分原因是对标准替莫唑胺治疗的耐药性。O 6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化状态是GBM患者烷基化化疗耐药的重要预后生物标志物。然而，MGMT甲基化状态鉴定方法，其中肿瘤组织通常采样不足，是耗时且昂贵的。目前，术前非侵入性成像方法用于鉴定生物标志物以预测MGMT甲基化状态。我们评估了一种新的基于放射组学的极限梯度增强（XGBoost）模型，以确定IDH 1野生型GBM患者的MGMT启动子甲基化状态。这项回顾性研究纳入了53例经病理证实的GBM患者，并检测了MGMT甲基化和IDH 1状态。从多模态MRI中提取放射组学特征，并通过F评分分析进行测试，以识别重要特征来改进我们的模型。我们确定了9个放射组学特征，其曲线下面积为0.896，优于先前报道的其他分类器。这些特征可能是鉴定IDH 1野生型GBM中MGMT甲基化状态的重要生物标志物。放射组学特征提取和F-核心特征选择的组合显着提高了XGBoost模型的性能，这可能对GBM的患者分层和治疗策略有影响。
Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs, characterized by extremely poor prognosis, partly due to resistance to standard temozolomide treatment. O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a crucial prognostic biomarker for alkylating chemotherapy resistance in patients with GBM. However, MGMT methylation status identification methods, where the tumor tissue is often undersampled, are time consuming and expensive. Currently, presurgical noninvasive imaging methods are used to identify biomarkers to predict MGMT methylation status. We evaluated a novel radiomics-based eXtreme Gradient Boosting (XGBoost) model to identify MGMT promoter methylation status in patients with IDH1 wildtype GBM. This retrospective study enrolled 53 patients with pathologically proven GBM and tested MGMT methylation and IDH1 status. Radiomics features were extracted from multimodality MRI and tested by F-score analysis to identify important features to improve our model. We identified nine radiomics features that reached an area under the curve of 0.896, which outperformed other classifiers reported previously. These features could be important biomarkers for identifying MGMT methylation status in IDH1 wildtype GBM. The combination of radiomics feature extraction and F-core feature selection significantly improved the performance of the XGBoost model, which may have implications for patient stratification and therapeutic strategy in GBM.
登录
查看更多内容
影响因子：
3.3
作者：
Jiang, Chendan;Kong, Ziren;Feng, Feng
通讯作者：
Feng, Feng
放射组学特征：预测早期（I 期或 II 期）非小细胞肺癌无病生存的潜在生物标志物
影响因子：
19.7
作者：
Huang, Yanqi;Liu, Zaiyi;Liang, Changhong
通讯作者：
Liang, Changhong
基于 F-18-FDG-PET 的放射组学特征可预测原发性弥漫性胶质瘤中 MGMT 启动子甲基化状态
影响因子：
4.9
作者：
Kong, Ziren;Lin, Yusong;Ma, Wenbin
通讯作者：
Ma, Wenbin
影响因子：
4.4
作者：
Clark, Kenneth;Vendt, Bruce;Prior, Fred
通讯作者：
Prior, Fred
基于深度学习的放射组学模型，用于预测多形性胶质母细胞瘤的生存期
影响因子：
4.6
作者：
Lao J;Chen Y;Li ZC;Li Q;Zhang J;Liu J;Zhai G
通讯作者：
Zhai G